Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«EPOR

Below is an extended EPOR patents listing. Click here to return to the gene page.

Patents :

US Patent No.Title
7208313 Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
7312089 Detection of erythropoietin and erythropoietin receptor
7332474 Peptides and related compounds having thrombopoietic activity
7348001 Tie1-binding ligands
7348139 SOCS-1 gene methylation in cancer
7348410 Flea head, nerve cord, hindgut and malpighian tubule proteins
7361493 Production of urokinase in a three-dimensional cell culture
7396913 Erythropoietin receptor binding antibodies
7410639 Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use
7414105 Peptides that bind to the erythropoietin receptor
7427401 Method of modulating leukemic cell and eosinphil activity with monoclonal antibodies
7309604 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
7307142 Leptin antagonists
7306799 Use of VEGF inhibitors for treatment of eye disorders
7220829 Cytokine binding domain of cytokine receptors
7223724 Use of vascular endothelial growth factor to treat photoreceptor cells
7223742 Enhanced solubility of recombinant proteins
7229962 Tetravalent etanercept
7256007 Methods of regulating cytokine signalling
7272508 Small molecule mimetics of erythropoietin
7291461 Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay
7300915 Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
7300916 Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
7303747 Use of VEGF inhibitors for treatment of eye disorders
7432051 Erythropoietin and erythropoietin receptor expression in human cancer
7435550 Methods of using cytokine receptor zalpha11 to detect its ligands
7566566 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
7569361 Thrombopoietin protein variants
7587286 Methods for rational pegylation of proteins
7588767 Microorganisms for therapy
7588771 Microorganisms for therapy
7590493 Methods for determining hepatotoxins
7598057 Use of cytokine receptors as biomarkers and therapeutic targets in human cancer
7608261 VEGF antagonist formulations suitable for intravitreal administration
7608425 Methods for protein expression in mammalian cells in serum-free medium
7610156 Methods for rational pegylation of proteins
7550433 Erythropoietin receptor peptide formulations and uses
7547820 Method for altering the nutritional content of plant seed
7547687 Therapeutic treatment methods
7459522 Peptide dimers as agonists of the erythropoietin (EPO) receptor, and associated methods of synthesis and use
7479270 Methods and compositions for activating VEGF-D and VEGF-C
7482334 Therapeutic treatment methods
7485297 Method of inhibition of vascular development using an antibody
7507787 Effectors of innate immunity
7517524 Immunointeractive molecules
7521049 Use of VEGF inhibitors for treatment of eye disorders
7524501 Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies
7528104 Peptides that bind to the erythropoietin receptor
7534604 Fusion polypeptides capable of activating receptors
7611711 VEGFR-3 inhibitor materials and methods

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.